Semaglutide as a Cornerstone Therapy in Obesity: Clinical and Pharmacological Insights

Semaglutide, a long-acting GLP-1 receptor agonist, is highlighted as a significant advancement in obesity treatment due to its substantial weight-reduction effects and metabolic benefits. It promotes weight loss by reducing appetite, enhancing satiety, delaying gastric emptying, and improving glucose homeostasis, with a convenient once-weekly dosing schedule. Clinical trials demonstrate notable reductions in body weight and improvements in glycemic control and cardiometabolic health across diverse patient groups. While gastrointestinal side effects are common, they typically decrease with gradual dose escalation. Although concerns like pancreatitis and thyroid-related risks are rare, they require clinical attention. Ongoing research into high-dose oral formulations and combination therapies may expand its clinical utility. Despite challenges related to cost and long-term safety, semaglutide is supported as a cornerstone therapy in obesity management.